Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Phase 3 Long-Term Extension (LTE) Study To Assess The Safety, Tolerability, And Efficacy Of Treatment With Pegtibatinase In Participants With Classical Homocystinuria (HCU) Due To Cystathionine Beta Synthase Deficiency (ENSEMBLE)

NCT06431893 is registered in ClinicalTrials.gov with Travere Therapeutics, Inc. as lead sponsor.

NCT NCT06431893
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06431893 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Phase 3 Long-Term Extension (LTE) Study To Assess The Safety, Tolerability, And Efficacy Of Treatment With Pegtibatinase In Participants With Classical Homocystinuria (HCU) Due To Cystathionine Beta Synthase Deficiency (ENSEMBLE)
Lead sponsor
Travere Therapeutics, Inc.
Phase
Phase 3
Overall status
Enrolling by invitation
Start date
April 30, 2024
Completion date
August 31, 2030
Enrollment
100 (estimated)
Sites
52

Conditions

As the registry lists them; a condition with its own page is linked.

homocystinuria